Edecesertib - Gilead Sciences
Alternative Names: GS-5718; Interleukin-1 receptor-associated kinase 4 inhibitor - Gilead SciencesLatest Information Update: 28 Oct 2024
At a glance
- Originator Gilead Sciences
- Class Anti-inflammatories; Antirheumatics; Skin disorder therapies; Small molecules
- Mechanism of Action IRAK4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cutaneous lupus erythematosus; Systemic lupus erythematosus
- No development reported Inflammation
- Discontinued Inflammatory bowel diseases; Rheumatoid arthritis
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for phase-I development in Inflammation(In volunteers) in Australia (PO, Tablet)
- 11 Aug 2023 Chemical structure information added
- 09 Aug 2023 Phase-II clinical trials in Systemic lupus erythematosus in USA (PO) prior to August 2023 (Gilead sciences pipeline, August 2023)